Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305682 · ClinicalTrials.gov registry record · Phase 2
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT00305682 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 295 participants.
The verdict
NCT00305682, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving sirolimus and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation followed by an umbilical cord blood transplant, sirolimus, and mycophenolate mofetil works in treating patients with hematologic cancer.
Interventions
- DRUG Fludarabine
- DRUG cyclophosphamide
- BIOLOGICAL anti-thymocyte globulin
- DRUG mycophenolate mofetil
- PROCEDURE umbilical cord blood transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2005-06 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305682
The ClinicalTrials.gov registry entry for NCT00305682 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00305682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305682 about?
NCT00305682 is a clinical study titled "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant". RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplan...
What is the current status of trial NCT00305682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2005-06. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT00305682?
The interventions under investigation include: Fludarabine (DRUG), cyclophosphamide (DRUG), anti-thymocyte globulin (BIOLOGICAL), mycophenolate mofetil (DRUG), umbilical cord blood transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00305682?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.